Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Apyx Medical CorpAPYX · Entity 6609 | Chief Financial Officer | January 11, 2023 | January 13, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Apyx Medical Corp
Report date January 11, 2023 · Filed January 13, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Option to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.50 · Expires 2033-01-11 | Direct | 96,000 |
Reported balance
After 2023-01-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-11 · Grant · Acquired 96,000 · Balance 96,000 F1: Reporting person was granted a stock option which shall vest ratably over a thirty six (36) month period and shall become fully vested and fully exercisable on the third anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Reporting person was granted a stock option which shall vest ratably over a thirty six (36) month period and shall become fully vested and fully exercisable on the third anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 11, 2023 Filed Jan 13, 2023 21:16 UTC | Apyx Medical Corp APYX · Entity 6609 | GrantStock Option (Option to Buy) · Derivative | 96,000 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0000719135-23-000004 · wf-form4_167364459379504.xml · derivative · entry 1 Semb Tara · CIK 0001764238 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,000 Underlying: Common Stock · 96,000 shares Expires 2033-01-11 F1 · derivative.exercise_date: Reporting person was granted a stock option which shall vest ratably over a thirty six (36) month period and shall become fully vested and fully exercisable on the third anniversary of the date of grant. Read SEC document |
| January 19, 2022 Filed Jan 31, 2022 23:10 UTC | Apyx Medical Corp APYX · Entity 6609 | GrantStock Option (Option to Buy) · Derivative | 96,000 | $0.00 Strike: $10.96 | $0.00 |
DisclosureSEC source: 0000719135-22-000006 · wf-form4_164367063565756.xml · derivative · entry 1 Semb Tara · CIK 0001764238 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,000 Underlying: Common Stock · 96,000 shares Expires 2032-01-19 F1 · derivative.exercise_date: Reporting person was granted a stock option which shall vest ratably over a thirty six (36) month period and shall become fully vested and fully exercisable on the third anniversary of the date of grant. Read SEC document |
| January 29, 2021 Filed Feb 9, 2021 15:32 UTC | Apyx Medical Corp APYX · Entity 6609 | GrantStock Option (Option to Buy) · Derivative | 48,000 | $0.00 Strike: $9.29 | $0.00 |
DisclosureSEC source: 0000719135-21-000006 · wf-form4_161288472777700.xml · derivative · entry 1 Semb Tara · CIK 0001764238 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,000 Underlying: Common Stock · 48,000 shares Expires 2031-01-29 F1 · derivative.exercise_date: Reporting person was granted a stock option which shall vest ratably over a thirty six (36) month period and shall become fully vested and fully exercisable on the third anniversary of the date of grant. Read SEC document |
| January 15, 2020 Filed Jan 22, 2020 22:16 UTC | Apyx Medical Corp APYX · Entity 6609 | GrantStock Option (Option to Buy) · Derivative | 96,000 | $0.00 Strike: $8.18 | $0.00 |
DisclosureSEC source: 0000719135-20-000008 · wf-form4_157973137956678.xml · derivative · entry 1 Semb Tara · CIK 0001764238 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,000 Underlying: Common Stock · 96,000 shares Expires 2030-01-15 F1 · derivative.exercise_date: Reporting person was granted a stock option which shall vest ratably over a thirty six (36) month period and shall become fully vested and fully exercisable on the third anniversary of the date of grant. Read SEC document |
| January 09, 2019 Filed Feb 12, 2019 00:19 UTC | Apyx Medical Corp APYX · Entity 6609 | GrantStock Option (Option to Buy) · Derivative | 65,000 | $0.00 Strike: $7.91 | $0.00 |
DisclosureSEC source: 0000719135-19-000016 · wf-form4_154993078378658.xml · derivative · entry 1 Semb Tara · CIK 0001764238 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2029-01-09 F1 · derivative.exercise_price: Reporting person was granted a stock option which shall vest ratably over a thirty six (36) month period and shall become fully vested and fully exercisable on the third anniversary of the date of grant. F1 · derivative.exercise_date: Reporting person was granted a stock option which shall vest ratably over a thirty six (36) month period and shall become fully vested and fully exercisable on the third anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.